CoChat
Sign Up
Cited by 42

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Midlife Chronological and Endocrinological Transitions in Brain Metabolism: System Biology Basis for Increased Alzheimer’s Risk in Female Brain

Wang, Yiwei, Shang, Yuan, Mishra, Aarti, Bacon, Eliza, Yin, Fei, Brinton, Roberta·2020·Scientific Reports
DOI 10.1038/s41598-020-65402-5PMC PMC7244485
Open this paper in CoChat — free account

Abstract

Decline in brain glucose metabolism is a hallmark of late-onset Alzheimer’s disease (LOAD). Comprehensive understanding of the dynamic metabolic aging process in brain can provide insights into windows of opportunities to promote healthy brain aging. Chronological and endocrinological aging are associated with brain glucose hypometabolism and mitochondrial adaptations in female brain. Using a rat model recapitulating fundamental features of the human menopausal transition, results of transcriptomic analysis revealed stage-specific shifts in bioenergetic systems of biology that were paralleled by bioenergetic dysregulation in midlife aging female brain. Transcriptomic profiles were predictive of outcomes from unbiased, discovery-based metabolomic and lipidomic analyses, which revealed a dynamic adaptation of the aging female brain from glucose centric to utilization of auxiliary fuel sources that included amino acids, fatty acids, lipids, and ketone bodies. Coupling between brain and peripheral metabolic systems was dynamic and shifted from uncoupled to coupled under metabolic stress. Collectively, these data provide a detailed profile across transcriptomic and metabolomic systems underlying bioenergetic function in brain and its relationship to peripheral metabolic responses. Mechanistically, these data provide insights into the complex dynamics of chronological and endocrinological bioenergetic aging in female brain. Translationally, these findings are predictive of initiation of the prodromal / preclinical phase of LOAD for women in midlife and highlight therapeutic windows of opportunity to reduce the risk of late-onset Alzheimer’s disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-020-65402-5

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Principle component analysis of hippocampal gene expression. PC1 can be explained by both chronological aging and endocrinological aging. Chronological aging has a stronger impact on the trancriptomic profile, especially post-menopausal, which led to a unique aging brain state.
Figure 1 Principle component analysis of hippocampal gene expression. PC1 can be explained by both chronological aging and endocrinological aging. Chronological aging has a stronger impact on the trancriptomic profile, especially post-menopausal, which led to a unique aging brain state.CC BY · PubMed Central
Figure 2 Gene expression of hippocampal electron transport chain subunits and bioenergetics regulators during endocrinological and chronological aging. Panel (a), nuclear encoded OXPHOS genes; (b), mitochondrial encoded OXPHOS genes; (c), expression of mitochondrial transcriptional factors, RNA polymerase POLRMT and DNA polymerase POLG; (d), gene expression of key bioenergetics regulators. *p < 0.05 in comparison to the previous column.
Figure 2 Gene expression of hippocampal electron transport chain subunits and bioenergetics regulators during endocrinological and chronological aging. Panel (a), nuclear encoded OXPHOS genes; (b), mitochondrial encoded OXPHOS genes; (c), expression of mitochondrial transcriptional factors, RNA polymerase POLRMT and DNA polymerase POLG; (d), gene expression of key bioenergetics regulators. *p < 0.05 in comparison to the previous column.CC BY · PubMed Central
Figure 3 Glycolysis and TCA cycle intermediates and key enzyme gene expression. Panel (a), glycolysis intermediates and lactate level; (b), TCA cycle intermediates and derivatives level; (c), gene expression of key enzymes involved in glycolysis; (d), gene expression of key enzymes involved in TCA cycle. *p < 0.05 in comparison to the previous column. #p < 0.05 in comparison to Reg 6 mo.
Figure 3 Glycolysis and TCA cycle intermediates and key enzyme gene expression. Panel (a), glycolysis intermediates and lactate level; (b), TCA cycle intermediates and derivatives level; (c), gene expression of key enzymes involved in glycolysis; (d), gene expression of key enzymes involved in TCA cycle. *p < 0.05 in comparison to the previous column. #p < 0.05 in comparison to Reg 6 mo.CC BY · PubMed Central
Figure 4 Brain amino acids levels (a) and gamma-glutamyl amino acids levels (b). *p < 0.05 compared to Reg 9 mo group.
Figure 4 Brain amino acids levels (a) and gamma-glutamyl amino acids levels (b). *p < 0.05 compared to Reg 9 mo group.CC BY · PubMed Central
Figure 5 Brain ketone body level (a) and expression of genes involved in ketone body metabolism (b). *p < 0.05 in comparison to the previous column. #p < 0.05 in comparison to Reg 6 mo.
Figure 5 Brain ketone body level (a) and expression of genes involved in ketone body metabolism (b). *p < 0.05 in comparison to the previous column. #p < 0.05 in comparison to Reg 6 mo.CC BY · PubMed Central
Figure 6 Glycolipids metabolism and expression of relevant genes. Panel (a), brain triglyceride levels; (b), DHAP, glycerol, and glycerol 3-phosphate levels; (c), gene expression of lipogenesis and lipolysis enzymes; (d), brain monoacylglycerol levels; (e), brain diacylglycerol levels. Lipids arranged by increased unsaturation and total carbon number from top to bottom for panels (a,d,e). *p < 0.05 compared to the previous column.
Figure 6 Glycolipids metabolism and expression of relevant genes. Panel (a), brain triglyceride levels; (b), DHAP, glycerol, and glycerol 3-phosphate levels; (c), gene expression of lipogenesis and lipolysis enzymes; (d), brain monoacylglycerol levels; (e), brain diacylglycerol levels. Lipids arranged by increased unsaturation and total carbon number from top to bottom for panels (a,d,e). *p < 0.05 compared to the previous column.CC BY · PubMed Central
Figure 7 Fatty acid metabolism. Panel (a), level of free fatty acid (FFA) levels in the brain; (b), level of acyl-carnitine levels in the brain; (c), gene expression of genes involved in fatty acid metabolism and β-oxidation. *p < 0.05 compared to the previous column. #p < 0.05 to Reg 6 mo group. &p < 0.05 to Reg 9 mo group.
Figure 7 Fatty acid metabolism. Panel (a), level of free fatty acid (FFA) levels in the brain; (b), level of acyl-carnitine levels in the brain; (c), gene expression of genes involved in fatty acid metabolism and β-oxidation. *p < 0.05 compared to the previous column. #p < 0.05 to Reg 6 mo group. &p < 0.05 to Reg 9 mo group.CC BY · PubMed Central
Figure 8 Plasma lipidomic analysis. Panel (a), free fatty acid levels; (b), acylcarnitine and free carnitine levels; (c), triglyceride (TAG) levels. *p < 0.05 to the previous column. #p < 0.05 to Reg 6 mo.
Figure 8 Plasma lipidomic analysis. Panel (a), free fatty acid levels; (b), acylcarnitine and free carnitine levels; (c), triglyceride (TAG) levels. *p < 0.05 to the previous column. #p < 0.05 to Reg 6 mo.CC BY · PubMed Central
Figure 9 Correlation of brain and plasma lipid profiles at each chronological and endocrinological aging stage. Panel (a), Reg 6 mo; (b), Reg 9 mo; (c), Irreg 9 mo; (d), Acyc 9 mo; (e), Acyc 15 mo; (f), summary of significant correlations between brain and plasma lipid species. Dark red indicates negative correlation, and bright yellow indicates positive correlation. FFA, free fatty acid; MAG, monoacylglycerol; DAG, diacylglycerol; TAG, triacylglycerol; SM, sphingomyelin; CER, ceramide; HCER, hexosylceramid; DCER, dihydroceramide; PC, phosphatidylcholine; PE, phosphatidylethanolamine; LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; CE, cholesterol ester.
Figure 9 Correlation of brain and plasma lipid profiles at each chronological and endocrinological aging stage. Panel (a), Reg 6 mo; (b), Reg 9 mo; (c), Irreg 9 mo; (d), Acyc 9 mo; (e), Acyc 15 mo; (f), summary of significant correlations between brain and plasma lipid species. Dark red indicates negative correlation, and bright yellow indicates positive correlation. FFA, free fatty acid; MAG, monoacylglycerol; DAG, diacylglycerol; TAG, triacylglycerol; SM, sphingomyelin; CER, ceramide; HCER, hexosylceramid; DCER, dihydroceramide; PC, phosphatidylcholine; PE, phosphatidylethanolamine; LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; CE, cholesterol ester.CC BY · PubMed Central
Figure 10 Dynamic metabolic aging in female brain during chronological and endocrinological aging. Decline in glucose metabolism results in utilization of amino acids as an interim metabolic fuel alternative, followed by activation of fatty acid metablism, as oxidative phosphorylation continues to decline.
Figure 10 Dynamic metabolic aging in female brain during chronological and endocrinological aging. Decline in glucose metabolism results in utilization of amino acids as an interim metabolic fuel alternative, followed by activation of fatty acid metablism, as oxidative phosphorylation continues to decline.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 79

  1. Bateman, R. J. et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 367, 795–804, https://doi.org/10.1056/NEJMoa1202753 (2012). · DOI · Paper page
  2. Reitz, C., Brayne, C. & Mayeux, R. Epidemiology of Alzheimer disease. Nature reviews. Neurology 7, 137–152, https://doi.org/10.1038/nrneurol.2011.2 (2011). · DOI · Paper page
  3. Brinton, R. D. Neurosteroids as regenerative agents in the brain: therapeutic implications. Nature reviews. Endocrinology 9, 241–250, https://doi.org/10.1038/nrendo.2013.31 (2013). · DOI
  4. De Santi, S. et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiology of aging 22, 529–539 (2001). · DOI · Paper page
  5. Ishii, K. et al. Reduction of cerebellar glucose metabolism in advanced Alzheimer’s disease. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 38, 925–928 (1997).
  6. Mosconi, L. et al. Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints. Biological psychiatry 63, 609–618, https://doi.org/10.1016/j.biopsych.2007.05.030 (2008). · DOI · Paper page
  7. Mosconi, L. et al. Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiology of aging 29, 676–692, https://doi.org/10.1016/j.neurobiolaging.2006.12.008 (2008). · DOI · Paper page
  8. Reiman, E. M. et al. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer’s disease. Proceedings of the National Academy of Sciences of the United States of America 98, 3334–3339, https://doi.org/10.1073/pnas.061509598 (2001). · DOI · Paper page
  9. Mosconi, L. et al. Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease. Neurology 72, 513–520, https://doi.org/10.1212/01.wnl.0000333247.51383.43 (2009). · DOI · Paper page
  10. Reiman, E. M. et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer’s dementia. Proceedings of the National Academy of Sciences of the United States of America 101, 284–289, https://doi.org/10.1073/pnas.2635903100 (2004). · DOI · Paper page
  11. Chetelat, G. et al. Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer’s disease? Neurology 60, 1374–1377 (2003). · DOI
  12. Willette, A. A. et al. Association of Insulin Resistance With Cerebral Glucose Uptake in Late Middle-Aged Adults at Risk for Alzheimer Disease. JAMA neurology 72, 1013–1020, https://doi.org/10.1001/jamaneurol.2015.0613 (2015). · DOI · Paper page
  13. Small, G. W. et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease. Proceedings of the National Academy of Sciences of the United States of America 97, 6037–6042, https://doi.org/10.1073/pnas.090106797 (2000). · DOI · Paper page
  14. Hyder, F. & Rothman, D. L. Quantitative fMRI and oxidative neuroenergetics. NeuroImage 62, 985–994, https://doi.org/10.1016/j.neuroimage.2012.04.027 (2012). · DOI
  15. Lin, A. L. & Rothman, D. L. What have novel imaging techniques revealed about metabolism in the aging brain? Future neurology 9, 341–354, https://doi.org/10.2217/fnl.14.13 (2014). · DOI
  16. de Leon, M. J. et al. Computed tomography and positron emission transaxial tomography evaluations of normal aging and Alzheimer’s disease. Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism 3, 391–394, https://doi.org/10.1038/jcbfm.1983.57 (1983). · DOI
  17. Hoyer, S. The young-adult and normally aged brain. Its blood flow and oxidative metabolism. A review–part I. Archives of gerontology and geriatrics 1, 101–116 (1982). · DOI
  18. Yin, F. et al. The perimenopausal aging transition in the female rat brain: decline in bioenergetic systems and synaptic plasticity. Neurobiology of aging 36, 2282–2295, https://doi.org/10.1016/j.neurobiolaging.2015.03.013 (2015). · DOI · Paper page
  19. Ding, F., Yao, J., Rettberg, J. R., Chen, S. & Brinton, R. D. Early Decline in Glucose Transport and Metabolism Precedes Shift to Ketogenic System in Female Aging and Alzheimer’s Mouse Brain: Implication for Bioenergetic Intervention. Plos One 8, e79977, https://doi.org/10.1371/journal.pone.0079977 (2013). · DOI · Paper page
  20. Yao, J. et al. Mitochondrial bioenergetic deficit precedes Alzheimer’s pathology in female mouse model of Alzheimer’s disease. Proceedings of the National Academy of Sciences of the United States of America 106, 14670–14675, https://doi.org/10.1073/pnas.0903563106 (2009). · DOI · Paper page
  21. Yao, J., Rettberg, J. R., Klosinski, L. P., Cadenas, E. & Brinton, R. D. Shift in brain metabolism in late onset Alzheimer’s disease: implications for biomarkers and therapeutic interventions. Molecular aspects of medicine 32, 247–257, https://doi.org/10.1016/j.mam.2011.10.005 (2011). · DOI
  22. Ding, F. et al. Ovariectomy induces a shift in fuel availability and metabolism in the hippocampus of the female transgenic model of familial Alzheimer’s. PloS One 8, e59825, https://doi.org/10.1371/journal.pone.0059825 (2013). · DOI
  23. Rettberg, J. R., Yao, J. & Brinton, R. D. Estrogen: a master regulator of bioenergetic systems in the brain and body. Front Neuroendocrinol 35, 8–30, https://doi.org/10.1016/j.yfrne.2013.08.001 (2014). · DOI · Paper page
  24. Yao, J. & Brinton, R. D. Estrogen regulation of mitochondrial bioenergetics: implications for prevention of Alzheimer’s disease. Advances in pharmacology (San Diego, Calif.) 64, 327–371, https://doi.org/10.1016/b978-0-12-394816-8.00010-6 (2012). · DOI
  25. Yao, J., Hamilton, R. T., Cadenas, E. & Brinton, R. D. Decline in mitochondrial bioenergetics and shift to ketogenic profile in brain during reproductive senescence. Biochimica et biophysica acta 1800, 1121–1126, https://doi.org/10.1016/j.bbagen.2010.06.002 (2010). · DOI
  26. Navarro, A. & Boveris, A. The mitochondrial energy transduction system and the aging process. American Journal of Physiology-Cell Physiology 292, C670–C686, https://doi.org/10.1152/ajpcell.00213.2006 (2007). · DOI · Paper page
  27. Boveris, A. & Navarro, A. Brain mitochondrial dysfunction in aging. IUBMB Life 60, 308–314, https://doi.org/10.1002/iub.46 (2008). · DOI · Paper page
  28. Maklashina, E. & Ackrell, B. A. C. Is defective electron transport at the hub of aging? Aging cell 3, 21–27, https://doi.org/10.1111/j.1474-9728.2003.00078.x (2003). · DOI
  29. Jones, T. T. & Brewer, G. J. Age-related deficiencies in complex I endogenous substrate availability and reserve capacity of complex IV in cortical neuron electron transport. Biochimica et Biophysica Acta (BBA) - Bioenergetics 1797, 167–176, https://doi.org/10.1016/j.bbabio.2009.09.009 (2010). · DOI
  30. Yao, J. et al. Ovarian hormone loss induces bioenergetic deficits and mitochondrial beta-amyloid. Neurobiology of aging 33, 1507–1521, https://doi.org/10.1016/j.neurobiolaging.2011.03.001 (2012). · DOI
  31. Klosinski, L. P. et al. White Matter Lipids as a Ketogenic Fuel Supply in Aging Female Brain: Implications for Alzheimer’s Disease. EBioMedicine 2, 1888–1904, https://doi.org/10.1016/j.ebiom.2015.11.002 (2015). · DOI
  32. Bowling, A. C. et al. Age-dependent impairment of mitochondrial function in primate brain. Journal of neurochemistry 60, 1964–1967 (1993). · DOI
  33. Ulfert, G., Schmidt, U. & Hoyer, S. Glucose and energy metabolism of rat cerebral cortex during aging. Experimental brain research Suppl 5, 102–111 (1982).
  34. Meier-Ruge, W., Iwangoff, P., Reichlmeier, K. & Sandoz, P. Neurochemical findings in the aging brain. Advances in biochemical psychopharmacology 23, 323–338 (1980).
  35. Mastroeni, D. Nuclear but not mitochondrial-encoded oxidative phosphorylation genes are altered in aging, mild cognitive impairment, and Alzheimer’s disease. 13, 510–519, https://doi.org/10.1016/j.jalz.2016.09.003 (2017). · DOI
  36. Zhu, X.-H., Lu, M., Lee, B.-Y., Ugurbil, K. & Chen, W. In vivo NAD assay reveals the intracellular NAD contents and redox state in healthy human brain and their age dependences. Proceedings of the National Academy of Sciences 112, 2876 (2015). · DOI · Paper page
  37. Ivanisevic, J. et al. Metabolic drift in the aging brain. Aging 8, 1000–1013, https://doi.org/10.18632/aging.100961 (2016). · DOI
  38. Mosconi, L. et al. Perimenopause and emergence of an Alzheimer’s bioenergetic phenotype in brain and periphery. Plos One 12, e0185926, https://doi.org/10.1371/journal.pone.0185926 (2017). · DOI
  39. Seshadri, S. et al. The lifetime risk of stroke: estimates from the Framingham Study. Stroke; a journal of cerebral circulation 37, 345–350, https://doi.org/10.1161/01.STR.0000199613.38911.b2 (2006). · DOI
  40. Paganini-Hill, A. & Henderson, V. W. Estrogen deficiency and risk of Alzheimer’s disease in women. American journal of epidemiology 140, 256–261 (1994). · DOI
  41. Brinton, R. D. The healthy cell bias of estrogen action: mitochondrial bioenergetics and neurological implications. Trends in neurosciences 31, 529–537, https://doi.org/10.1016/j.tins.2008.07.003 (2008). · DOI
  42. Pellerin, L. Food for thought: the importance of glucose and other energy substrates for sustaining brain function under varying levels of activity. Diabetes & metabolism 36(Suppl 3), S59–63, https://doi.org/10.1016/s1262-3636(10)70469-9 (2010). · DOI
  43. Lin, A. L., Zhang, W., Gao, X. & Watts, L. Caloric restriction increases ketone bodies metabolism and preserves blood flow in aging brain. Neurobiology of aging 36, 2296–2303, https://doi.org/10.1016/j.neurobiolaging.2015.03.012 (2015). · DOI · Paper page
  44. Guzman, M. & Blazquez, C. Ketone body synthesis in the brain: possible neuroprotective effects. Prostaglandins, leukotrienes, and essential fatty acids 70, 287–292, https://doi.org/10.1016/j.plefa.2003.05.001 (2004). · DOI
  45. Morris, A. A. Cerebral ketone body metabolism. Journal of inherited metabolic disease 28, 109–121, https://doi.org/10.1007/s10545-005-5518-0 (2005). · DOI
  46. Brinton, R. D., Yao, J., Yin, F., Mack, W. J. & Cadenas, E. Perimenopause as a neurological transition state. Nature reviews. Endocrinology, https://doi.org/10.1038/nrendo.2015.82 (2015). · DOI · Paper page
  47. Wang, Y. From Risk Mitochondrial and Metabolic Phenotype Towards a Precision Medicine Approach for Alzheimer’s Disease 27798664 thesis, University of Southern California, (2018).
  48. Shang, Y. et al. Evidence in support of chromosomal sex influencing plasma based metabolome vs APOE genotype influencing brain metabolome profile in humanized APOE male and female mice. Plos One 15, e0225392, https://doi.org/10.1371/journal.pone.0225392 (2020). · DOI
  49. Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq quantification. Nature biotechnology 34, 525–527, https://doi.org/10.1038/nbt.3519 (2016). · DOI · Paper page
  50. Soneson, C., Love, M. I. & Robinson, M. D. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. F1000Research 4, 1521, https://doi.org/10.12688/f1000research.7563.2 (2015). · DOI · Paper page
  51. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq. 2. Genome Biol 15, 550, https://doi.org/10.1186/s13059-014-0550-8 (2014). · DOI · Paper page
  52. Bacon, E. R. et al. Neuroendocrine aging precedes perimenopause and is regulated by DNA methylation. Neurobiology of aging 74, 213–224, https://doi.org/10.1016/j.neurobiolaging.2018.09.029 (2019). · DOI
  53. Villemagne, V. L. et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. The Lancet. Neurology 12, 357–367, https://doi.org/10.1016/s1474-4422(13)70044-9 (2013). · DOI · Paper page
  54. Wilson, R. S., Leurgans, S. E., Boyle, P. A. & Bennett, D. A. Cognitive decline in prodromal Alzheimer disease and mild cognitive impairment. Arch Neurol 68, 351–356, https://doi.org/10.1001/archneurol.2011.31 (2011). · DOI · Paper page
  55. Barnes, J. et al. Alzheimer’s disease first symptoms are age dependent: Evidence from the NACC dataset. Alzheimer’s &. dementia: the journal of the Alzheimer’s Association 11, 1349–1357, https://doi.org/10.1016/j.jalz.2014.12.007 (2015). · DOI
  56. Gold, E. B. The timing of the age at which natural menopause occurs. Obstetrics and gynecology clinics of North America 38, 425–440, https://doi.org/10.1016/j.ogc.2011.05.002 (2011). · DOI
  57. Brookmeyer, R., Gray, S. & Kawas, C. Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. American journal of public health 88, 1337–1342 (1998). · DOI
  58. Brookmeyer, R. et al. National estimates of the prevalence of Alzheimer’s disease in the United States. Alzheimer’s &. dementia: the journal of the Alzheimer’s Association 7, 61–73, https://doi.org/10.1016/j.jalz.2010.11.007 (2011). · DOI
  59. Riedel, B. C., Thompson, P. M. & Brinton, R. D. Age, APOE and sex: Triad of risk of Alzheimer’s disease. The Journal of Steroid Biochemistry and Molecular Biology 160, 134–147, https://doi.org/10.1016/j.jsbmb.2016.03.012 (2016). · DOI · Paper page
  60. Mosconi, L. et al. Sex differences in Alzheimer risk: Brain imaging of endocrine vs chronologic aging. Neurology 89, 1382–1390, https://doi.org/10.1212/WNL.0000000000004425 (2017). · DOI · Paper page
  61. Zhang, J. et al. Acylcarnitines as markers of exercise-associated fuel partitioning, xenometabolism, and potential signals to muscle afferent neurons. Experimental physiology 102, 48–69, https://doi.org/10.1113/ep086019 (2017). · DOI
  62. Adams, S. H. et al. Plasma Acylcarnitine Profiles Suggest Incomplete Long-Chain Fatty Acid β-Oxidation and Altered Tricarboxylic Acid Cycle Activity in Type 2 Diabetic African-American Women. J Nutr 139, 1073–1081, https://doi.org/10.3945/jn.108.103754 (2009). · DOI · Paper page
  63. Nugent, S. et al. Brain glucose and acetoacetate metabolism: a comparison of young and older adults. Neurobiology of aging 35, 1386–1395, https://doi.org/10.1016/j.neurobiolaging.2013.11.027 (2014). · DOI
  64. Blalock, E. M. et al. Incipient Alzheimer’s disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proceedings of the National Academy of Sciences of the United States of America 101, 2173–2178, https://doi.org/10.1073/pnas.0308512100 (2004). · DOI · Paper page
  65. Kakimoto, A. et al. Age-Related Sex-Specific Changes in Brain Metabolism and Morphology. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 57, 221–225, https://doi.org/10.2967/jnumed.115.166439 (2016). · DOI
  66. Shen, X., Liu, H., Hu, Z., Hu, H. & Shi, P. The Relationship between Cerebral Glucose Metabolism and Age: Report of a Large Brain PET Data Set. Plos One 7, e51517, https://doi.org/10.1371/journal.pone.0051517 (2012). · DOI
  67. Salminen, E. K., Portin, R. I., Koskinen, A., Helenius, H. & Nurmi, M. Associations between serum testosterone fall and cognitive function in prostate cancer patients. Clinical cancer research: an official journal of the American Association for Cancer Research 10, 7575–7582, https://doi.org/10.1158/1078-0432.Ccr-04-0750 (2004). · DOI
  68. Almeida, O. P., Waterreus, A., Spry, N., Flicker, L. & Martins, R. N. One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men. Psychoneuroendocrinology 29, 1071–1081, https://doi.org/10.1016/j.psyneuen.2003.11.002 (2004). · DOI
  69. Cherrier, M. M., Rose, A. L. & Higano, C. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. The Journal of urology 170, 1808–1811, https://doi.org/10.1097/01.ju.0000091640.59812.83 (2003). · DOI
  70. Beauchet, O. Testosterone and cognitive function: current clinical evidence of a relationship. European journal of endocrinology 155, 773–781, https://doi.org/10.1530/eje.1.02306 (2006). · DOI
  71. Grimm, A., Mensah-Nyagan, A. G. & Eckert, A. Alzheimer, mitochondria and gender. Neuroscience and biobehavioral reviews 67, 89–101, https://doi.org/10.1016/j.neubiorev.2016.04.012 (2016). · DOI
  72. Gaignard, P. et al. Role of Sex Hormones on Brain Mitochondrial Function, with Special Reference to Aging and Neurodegenerative Diseases. Frontiers in aging neuroscience 9, https://doi.org/10.3389/fnagi.2017.00406 (2017). · DOI
  73. Hogervorst, E. et al. Serum total testosterone is lower in men with Alzheimer’s disease. Neuro endocrinology letters 22, 163–168 (2001).
  74. Rosario, E. R., Chang, L., Stanczyk, F. Z. & Pike, C. J. Age-Related Testosterone Depletion and the Development of Alzheimer Disease. JAMA 292, 1431–1432, https://doi.org/10.1001/jama.292.12.1431-b (2004). · DOI
  75. Moffat, S. D. et al. Free testosterone and risk for Alzheimer disease in older men. Neurology 62, 188, https://doi.org/10.1212/WNL.62.2.188 (2004). · DOI
  76. Schönfeld, P. & Reiser, G. Why does brain metabolism not favor burning of fatty acids to provide energy? - Reflections on disadvantages of the use of free fatty acids as fuel for brain. Journal of Cerebral Blood Flow & Metabolism 33, 1493–1499, https://doi.org/10.1038/jcbfm.2013.128 (2013). · DOI · Paper page
  77. Blazquez, C., Sanchez, C., Daza, A., Galve-Roperh, I. & Guzman, M. The stimulation of ketogenesis by cannabinoids in cultured astrocytes defines carnitine palmitoyltransferase I as a new ceramide-activated enzyme. Journal of neurochemistry 72, 1759–1768 (1999). · DOI
  78. Edmond, J., Higa, T. A., Korsak, R. A., Bergner, E. A. & Lee, W. N. Fatty acid transport and utilization for the developing brain. Journal of neurochemistry 70, 1227–1234 (1998). · DOI
  79. Edmond, J., Robbins, R. A., Bergstrom, J. D., Cole, R. A. & de Vellis, J. Capacity for substrate utilization in oxidative metabolism by neurons, astrocytes, and oligodendrocytes from developing brain in primary culture. Journal of neuroscience research 18, 551–561, https://doi.org/10.1002/jnr.490180407 (1987). · DOI

Cited by

Sorted by citations

See all 42

Metadata

Authors
Wang, Y., Shang, Y., Mishra, A., Bacon, E., Yin, F., & Brinton, R.
Venue
Scientific Reports
Publisher
Springer Science and Business Media LLC
Published
2020-05-22
Volume
10
Issue
1
ISSN
2045-2322
DOI
10.1038/s41598-020-65402-5
PMC
PMC7244485
Cited by
42
References
9
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review